TPI Enterprises Overview

  • Founded
  • 2004

Founded
  • Status
  • Public

  • Investments
  • 2

  • Share Price
  • $0.21

  • (As of Friday Closing)

TPI Enterprises General Information

Description

Palla Pharma Ltd is a licensed poppy processor in Australia. It is engaged in producing narcotic raw material for the international pharmaceutical industry. It also supplies narcotic raw material and culinary poppy seed.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Primary Office
  • P.O. Box 2139
  • Melbourne, Victoria 3001
  • Australia
+61 (03) 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TPI Enterprises Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.21 $0.21 $0.14 - $0.61 $34.1M 162M 91.7K -$0.30

TPI Enterprises Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 55,413 92,220 95,437 80,451
Revenue 12,457 15,066 38,007 34,465
EBITDA (40,394) (20,675) (1,511) (1,917)
Net Income (43,872) (23,905) (5,310) (4,321)
Total Assets 37,482 51,836 62,708 58,999
Total Debt 11,685 14,252 3,828 16,109
Public Fundamental Data provided by Morningstar, Inc. disclaimer

TPI Enterprises Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore TPI Enterprises‘s full profile, request access.

Request a free trial

TPI Enterprises Patents

TPI Enterprises Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2872079-A1 Papaver bracteatum with modified alkaloid content Abandoned 30-Apr-2012 00000000000
US-20140013465-A1 Papaver bracteatum with modified alkaloid content Abandoned 30-Apr-2012 00000000000
EP-2635107-A1 Papaver bracteatum with modified alkaloid content Withdrawn 01-Nov-2010 0000000000
EP-2635107-A4 Papaver bracteatum with modified alkaloid content Withdrawn 01-Nov-2010 0000000000
CA-2727944-A1 Process for the synthesis of n-demethylated morphinane compounds Abandoned 20-Jun-2008 C07D221/28
To view TPI Enterprises’s complete patent history, request access »

TPI Enterprises Executive Team (3)

Name Title Board Seat Contact Info
Jarrod Ritchie Chief Executive Officer, Managing Director, Executive Director, Founder & Board Member
Mark Glassford President & Board Member
Roger McPherson Chief Financial Officer & Company Secretary
To view TPI Enterprises’s complete executive team members history, request access »

TPI Enterprises Board Members (5)

Name Representing Role Since
Mark Glassford TPI Enterprises President & Board Member 000 0000
Peter Robinson TPI Enterprises Chairman 000 0000
Simon Moore Self Board Member 000 0000
Todd Barlow Self Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

TPI Enterprises Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore TPI Enterprises‘s full profile, request access.

Request a free trial

TPI Enterprises Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 02-Oct-2017 0000000000 000.00 Other Healthcare Services 000000 00
TPI Enterprises (Lisbon facility) 01-Jun-2015 Corporate Asset Purchase Buildings and Property
To view TPI Enterprises’s complete investments and acquisitions history, request access »

TPI Enterprises Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000 00000000000 (0 01-Jun-2015 000000000 00000 00 Completed
  • 000 00000000000
To view TPI Enterprises’s complete exits history, request access »